JP2013507369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507369A5 JP2013507369A5 JP2012533264A JP2012533264A JP2013507369A5 JP 2013507369 A5 JP2013507369 A5 JP 2013507369A5 JP 2012533264 A JP2012533264 A JP 2012533264A JP 2012533264 A JP2012533264 A JP 2012533264A JP 2013507369 A5 JP2013507369 A5 JP 2013507369A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- hydrogen
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- -1 2-ethylbutoxy, 4-ethylphenyl Chemical group 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 208000006888 Agnosia Diseases 0.000 claims 1
- 241001047040 Agnosia Species 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- WTNZAPZOSSPUHI-ACRUOGEOSA-N CCC(CC)COc1ccc([C@H](CO)NC([C@@H](C2)[C@H]2c2ccc[s]2)=O)c(C)c1 Chemical compound CCC(CC)COc1ccc([C@H](CO)NC([C@@H](C2)[C@H]2c2ccc[s]2)=O)c(C)c1 WTNZAPZOSSPUHI-ACRUOGEOSA-N 0.000 description 2
- FDGXWFLFJLMESD-FBOXXWIASA-N CCCC(C)COc1ccc([C@H](CO)NC([C@@H](C2)[C@H]2c2ccc[s]2)=O)cc1 Chemical compound CCCC(C)COc1ccc([C@H](CO)NC([C@@H](C2)[C@H]2c2ccc[s]2)=O)cc1 FDGXWFLFJLMESD-FBOXXWIASA-N 0.000 description 2
- XXQRMVONZZWLKF-DSITVLBTSA-N CC[C@@H](c(cc1)ccc1-c(cc1)ccc1OC)NC([C@@H](C1)[C@H]1c1ccccc1)=O Chemical compound CC[C@@H](c(cc1)ccc1-c(cc1)ccc1OC)NC([C@@H](C1)[C@H]1c1ccccc1)=O XXQRMVONZZWLKF-DSITVLBTSA-N 0.000 description 2
- OHWJVFXCFOFCAJ-ZFCZOSEKSA-N CC[C@H](C)COc1ccc([C@H](CO)NC([C@@H](C2)[C@H]2C2=CC=CSC2)=O)cc1 Chemical compound CC[C@H](C)COc1ccc([C@H](CO)NC([C@@H](C2)[C@H]2C2=CC=CSC2)=O)cc1 OHWJVFXCFOFCAJ-ZFCZOSEKSA-N 0.000 description 2
- DCGJSXHMNZQIQN-FKBYEOEOSA-N CCc(cc1)ccc1-c1cc(OC)c([C@H](CO)NC([C@@H](C2)[C@H]2c2ccc[s]2)=O)cc1 Chemical compound CCc(cc1)ccc1-c1cc(OC)c([C@H](CO)NC([C@@H](C2)[C@H]2c2ccc[s]2)=O)cc1 DCGJSXHMNZQIQN-FKBYEOEOSA-N 0.000 description 2
- FTJGKCRCBGQPIG-NJYVYQBISA-N Cc(cc1)ccc1-c1ccc([C@H](CO)NC([C@H](C2)[C@@H]2c2ccc[s]2)=O)cc1 Chemical compound Cc(cc1)ccc1-c1ccc([C@H](CO)NC([C@H](C2)[C@@H]2c2ccc[s]2)=O)cc1 FTJGKCRCBGQPIG-NJYVYQBISA-N 0.000 description 2
- FYZYWDQJQHRPHP-VJBWXMMDSA-N CCC(CC)COc1cc(OC)c([C@H](CO)NC([C@@H](C2)[C@H]2c2ccccc2)=O)cc1 Chemical compound CCC(CC)COc1cc(OC)c([C@H](CO)NC([C@@H](C2)[C@H]2c2ccccc2)=O)cc1 FYZYWDQJQHRPHP-VJBWXMMDSA-N 0.000 description 1
- OGUKXDBWPDCVQH-FIDFUJNHSA-N CCC(CC)COc1ccc([C@H](CO)NC([C@@H](C2)[C@H]2[C@@H](C)S/C=C\C)=O)cc1 Chemical compound CCC(CC)COc1ccc([C@H](CO)NC([C@@H](C2)[C@H]2[C@@H](C)S/C=C\C)=O)cc1 OGUKXDBWPDCVQH-FIDFUJNHSA-N 0.000 description 1
- XAHXNNMINZURBD-FHWLQOOXSA-N CCCC#Cc1cc(OC)c([C@H](CO)NC([C@@H](C2)[C@H]2c2ccc[s]2)=O)cc1 Chemical compound CCCC#Cc1cc(OC)c([C@H](CO)NC([C@@H](C2)[C@H]2c2ccc[s]2)=O)cc1 XAHXNNMINZURBD-FHWLQOOXSA-N 0.000 description 1
- GZWRROHMJHBEIT-IGYPZXGCSA-N CCCC(C)COc1cc(C)c([C@H](CO)NC([C@@H](C2)[C@H]2c2ccc[s]2)=O)cc1 Chemical compound CCCC(C)COc1cc(C)c([C@H](CO)NC([C@@H](C2)[C@H]2c2ccc[s]2)=O)cc1 GZWRROHMJHBEIT-IGYPZXGCSA-N 0.000 description 1
- QCKLCYQHRUEFHE-FQNOENOBSA-N CCCC(C)COc1ccc([C@H](CN2CCN(C)CC2)NC([C@@H](C2)[C@H]2c2ccc[s]2)=O)cc1 Chemical compound CCCC(C)COc1ccc([C@H](CN2CCN(C)CC2)NC([C@@H](C2)[C@H]2c2ccc[s]2)=O)cc1 QCKLCYQHRUEFHE-FQNOENOBSA-N 0.000 description 1
- DMGNMWDPZBEJER-NSHDSACASA-N CC[C@H](C)COc1cc(C)c(CCN)cc1 Chemical compound CC[C@H](C)COc1cc(C)c(CCN)cc1 DMGNMWDPZBEJER-NSHDSACASA-N 0.000 description 1
- YESANJKNYPTWPX-DSYPUSFNSA-N CC[C@H](C)COc1cc(C)c([C@H](CO)NC([C@@H](C2)[C@H]2c2ccc[s]2)=O)cc1 Chemical compound CC[C@H](C)COc1cc(C)c([C@H](CO)NC([C@@H](C2)[C@H]2c2ccc[s]2)=O)cc1 YESANJKNYPTWPX-DSYPUSFNSA-N 0.000 description 1
- RMQLXXLULAKNOG-ACRUOGEOSA-N Cc(cc1)ccc1-c1cc(OC)c([C@H](CO)NC([C@@H](C2)[C@H]2c2ccc[s]2)=O)cc1 Chemical compound Cc(cc1)ccc1-c1cc(OC)c([C@H](CO)NC([C@@H](C2)[C@H]2c2ccc[s]2)=O)cc1 RMQLXXLULAKNOG-ACRUOGEOSA-N 0.000 description 1
- FTJGKCRCBGQPIG-ACRUOGEOSA-N Cc(cc1)ccc1-c1ccc([C@H](CO)NC([C@@H](C2)[C@H]2c2ccc[s]2)=O)cc1 Chemical compound Cc(cc1)ccc1-c1ccc([C@H](CO)NC([C@@H](C2)[C@H]2c2ccc[s]2)=O)cc1 FTJGKCRCBGQPIG-ACRUOGEOSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24946509P | 2009-10-07 | 2009-10-07 | |
| US61/249,465 | 2009-10-07 | ||
| PCT/US2010/051572 WO2011044195A1 (en) | 2009-10-07 | 2010-10-06 | Modulators of g protein-coupled receptor 88 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013507369A JP2013507369A (ja) | 2013-03-04 |
| JP2013507369A5 true JP2013507369A5 (enExample) | 2013-11-21 |
Family
ID=43480829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012533264A Withdrawn JP2013507369A (ja) | 2009-10-07 | 2010-10-06 | Ｇタンパク質共役受容体８８の調節因子 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8497271B2 (enExample) |
| EP (1) | EP2486030B1 (enExample) |
| JP (1) | JP2013507369A (enExample) |
| CN (1) | CN102686575A (enExample) |
| ES (1) | ES2428492T3 (enExample) |
| IN (1) | IN2012DN02876A (enExample) |
| WO (1) | WO2011044195A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8426414B2 (en) | 2009-10-09 | 2013-04-23 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| US8304577B2 (en) | 2009-10-09 | 2012-11-06 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| HRP20180913T1 (hr) * | 2011-07-08 | 2018-07-27 | H. Lundbeck A/S | Pozitivni alosterni modulatori receptora nikotinskog acetilkolina |
| UA111746C2 (uk) * | 2011-07-08 | 2016-06-10 | Х. Луннбек А/С | Позитивні алостеричні модулятори нікотинового рецептора ацетилхоліну |
| US8703953B2 (en) | 2012-03-09 | 2014-04-22 | Bristol-Myers Squibb Company | Aryl ether-base kinase inhibitors |
| WO2014006120A1 (en) * | 2012-07-06 | 2014-01-09 | H. Lundbeck A/S | New positive allosteric modulators of nicotinic acetylcholine receptor |
| EP2928860A1 (en) * | 2012-12-10 | 2015-10-14 | H. Lundbeck A/S | New positive allosteric modulators of nicotinic acetylcholine receptor |
| WO2015006100A1 (en) | 2013-07-08 | 2015-01-15 | Bristol-Myers Squibb Company | Aryl amide kinase inhibitors |
| CN105979950A (zh) | 2013-10-11 | 2016-09-28 | 百时美施贵宝公司 | 吡咯并三嗪激酶抑制剂 |
| CN113005089A (zh) * | 2019-12-20 | 2021-06-22 | 泰州医药城国科化物生物医药科技有限公司 | 一种无标记细胞膜受体gpr88的细胞筛选模型及应用 |
| CN111592531B (zh) * | 2020-06-23 | 2023-08-15 | 上海鲲博玖瑞医药科技发展有限公司 | 福瑞塞替的制备方法 |
| GB202209193D0 (en) | 2022-06-22 | 2022-08-10 | Pandeia Therapeutics Ltd | Modulators of g protein-coupled receptor 88 |
| GB202209195D0 (en) | 2022-06-22 | 2022-08-10 | Pandeia Therapeutics Ltd | Modulators of g protein-coupled receptor 88 |
| WO2026055419A1 (en) | 2024-09-05 | 2026-03-12 | Acadia Pharmaceuticals Inc. | Modulators of g protein-coupled receptor 88 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0672031T3 (da) | 1992-12-02 | 2003-06-10 | Pfizer | Catecholdiethere som selektive PDE IV-inhibitorer |
| US5709861A (en) | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
| AU760889B2 (en) * | 1998-10-14 | 2003-05-22 | Ortho-Mcneil Pharmaceutical, Inc. | 1,2-disubstituted cyclopropanes |
| ATE388946T1 (de) | 2002-04-05 | 2008-03-15 | Boehringer Ingelheim Pharma | Cyanamide als reversible hemmer von cystein proteasen |
| WO2003103666A2 (en) | 2002-06-07 | 2003-12-18 | Altana Pharma Ag | Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones |
| EP1565190A4 (en) | 2002-11-22 | 2006-04-26 | Bristol Myers Squibb Co | ARYLCYCLOPROPYLCARBOXYLIC ACID AMIDE AS A KALIUM CHANNEL OPENER |
| WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| EP1593667A4 (en) | 2003-02-12 | 2009-03-04 | Takeda Pharmaceutical | Amine derivative |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| WO2005051890A1 (en) | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
| CA2570694A1 (en) | 2004-06-24 | 2006-02-02 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| US20080153917A1 (en) | 2004-09-10 | 2008-06-26 | Ucb Pharma, S.A. | Sigma Receptor Ligands |
| EA200701745A1 (ru) * | 2005-03-17 | 2008-06-30 | Пфайзер, Инк. | Циклопропанкарбоксамидные производные |
| CN100494167C (zh) | 2005-08-02 | 2009-06-03 | 天津大学 | 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用 |
| JP2007217408A (ja) | 2006-01-19 | 2007-08-30 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| JP5420395B2 (ja) | 2006-04-07 | 2014-02-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｐ結合カセット輸送体の調節剤 |
| WO2007129188A1 (en) | 2006-05-10 | 2007-11-15 | Pfizer Japan Inc. | Cyclopropanecarboxamide compound |
| US20080040819A1 (en) | 2006-08-14 | 2008-02-14 | Wyeth | Methods of identifying agents for treatment of schizophrenia and related disorders |
| US8304577B2 (en) | 2009-10-09 | 2012-11-06 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| US8426414B2 (en) | 2009-10-09 | 2013-04-23 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
-
2010
- 2010-10-01 US US12/895,916 patent/US8497271B2/en active Active
- 2010-10-06 JP JP2012533264A patent/JP2013507369A/ja not_active Withdrawn
- 2010-10-06 CN CN2010800552740A patent/CN102686575A/zh active Pending
- 2010-10-06 ES ES10765715T patent/ES2428492T3/es active Active
- 2010-10-06 EP EP10765715.7A patent/EP2486030B1/en not_active Not-in-force
- 2010-10-06 IN IN2876DEN2012 patent/IN2012DN02876A/en unknown
- 2010-10-06 WO PCT/US2010/051572 patent/WO2011044195A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013507374A5 (enExample) | ||
| JP2015501783A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2015505296A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| JP2011519854A5 (enExample) | ||
| RU2015151502A (ru) | Химические соединения | |
| JP2016528301A5 (enExample) | ||
| JP2011500550A5 (enExample) | ||
| JP2018537535A5 (enExample) | ||
| JP2013533253A5 (enExample) | ||
| JP2012041349A5 (enExample) | ||
| JP2014521625A5 (enExample) | ||
| JP2008501000A5 (enExample) | ||
| JP2018507899A5 (enExample) | ||
| JP2015512931A5 (enExample) | ||
| ME02452B (me) | Sredstva za induciranje apoptoze namijenjena liječenju raka i imunih i autoimunih bolesti | |
| RU2009136592A (ru) | Терапевтические агенты | |
| JP2017508782A5 (enExample) | ||
| JP2013507371A5 (enExample) | ||
| JP2013536188A5 (enExample) | ||
| JP2012512863A5 (enExample) | ||
| JP2015511609A5 (enExample) | ||
| JP2014516033A5 (enExample) | ||
| JP2013542963A5 (enExample) |